坦辛IIA通过调节FBXO11表达来缓解IL-1β诱导的慢性细胞亡和炎症
Jin Xu1, XiaoCheng Zhi1, YunHui Zhang1
1Department of Orthopaedics, Shanghai Baoshan Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai City, China.
Clinics (Sao Paulo, Brazil)
|April 27, 2024
概括
坦辛IIA (TAN IIA) 显示出抗亡和抗炎作用,为骨关节炎 (OA) 提供潜在的治疗方法. 这种化合物通过抑制关键信号通路来缓解状细胞损伤,从而延迟了OA的进展.
科学领域:
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 骨关节炎 (OA) 是一种退行性关节疾病,其特征是软骨的分解和炎症.
- 介素-1β (IL-1β) 是一种关键的促炎性细胞因子,涉及到OA的发病.
- 坦辛IIA (TAN IIA) 是一种具有潜在治疗功能的天然化合物.
研究的目的:
- 阐明TAN IIA在治疗骨关节炎 (OA) 的药理机制.
- 研究TAN IIA对状细胞亡和炎症的影响.
- 评估TAN IIA在体内OA大鼠模型中的治疗潜力.
主要方法:
- 在体外:CHON-001细胞用IL-1β和TAN IIA进行治疗;评估了生命力,亡和炎症标记物 (TNF-α,IL-6,iNOS).
- 在体内:建立了OA大鼠模型,并用不同剂量的TAN IIA进行治疗;评估了软骨破坏,亡和炎症.
- 分子分析包括西斑,RT-qPCR,ELISA,TUNEL,HE染色和免疫组织化学.
主要成果:
- 在CHON-001细胞中,IL-1β诱导了亡和炎症,这些细胞被TAN IIA减弱.
- TAN IIA下调FBXO11表达,抑制PI3K/AKT和NF-κB通路.
- 在OA大鼠中,TAN IIA治疗减少了冠状细胞亡,炎症和软骨破坏.
结论:
- 在OA中,TAN IIA通过降低FBXO11的调节和抑制PI3K/Akt和NF-κB通路,表现出抗亡和抗炎作用.
- TAN IIA减轻了状细胞的亡和炎症,这表明它有可能延迟OA的进展.
- 这些发现支持TAN IIA作为骨关节炎的有前途的治疗剂.
相关概念视频
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
01:16TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
02:26NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K